title: The next phase of real-world clinical experience with alefacept: the AWARE-2 registry.
authors.affiliation: Keystone Dermatology Institute, Edmonton, AB. gesearles@mac.com
authors.forename: Gordon
authors.initials: G
authors.lastname: Searles
authors.forename: Robert
authors.initials: R
authors.lastname: Bissonnette
authors.forename: Ian
authors.initials: I
authors.lastname: Landells
authors.forename: Neil H
authors.initials: NH
authors.lastname: Shear
mesh_terms: D000077944:Alefacept; D002170:Canada / Q000453:epidemiology; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D009017:Morbidity / Q000639:trends; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012042:Registries; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept